[KIM, Eunhee 김은희, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, BAE, Hyun-Ju 배현주, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, BAE, Hyun-Ju 배현주, KIM, Jin-Woo 김진우, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, BAE, Hyun-Ju 배현주, KIM, Jin-Woo 김진우, IN, Tae-Kyu 인태규, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, BAE, Hyun-Ju 배현주, KIM, Jin-Woo 김진우, IN, Tae-Kyu 인태규, JOO, Choun-Ki 주천기] 99 Daehak-ro, Yuseong-gu 305-764 대전광역시 유성구 대학로99, DaejeonDaejeon 305-764 The present invention relates to a novel indene derivative, a preparation method for same, and a pharmaceutical composition, for preventing or treating retinal diseases, containing same as an active ingredient. A novel indene derivative, an optical isomer of same, or pharmaceutically acceptable salts of same, according to the present invention, has excellent inhibitory efficiency of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Therefore, a composition containing same as an active ingredient can be utilized as a pharmaceutical composition for preventing or treating retinal diseases such as retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardts disease, Usher syndrome, choroideremia, rod-cone or cone-rod dystrophy, ciliopathy, mitochondrial disorders, progressive retinal atrophy, degenerative retinal diseases, age-related macular degeneration (AMD), wet AMD, dry AMD, geographical atrophy, inherited or acquired macular degeneration, retinal photoreceptor diseases, retinal pigment epithelial diseases, diabetic retinopathy, cystic macular edema, uveitis, retinal detachment, traumatic retinal injury, iatrogenic retinal injury, macular holes, macular capillarectasia, ganglion cell diseases, optic nerve diseases, glaucoma, optic neuropathy, ischemic retinal diseases, retinopathy of prematurity, occlusion of retinal vessels, inherited macroaneurysm, retinal vascular diseases, ophthalmic vascular diseases, glaucomatous retinal neurodegeneration, ischemic optic neuropathy and the like.

[KIM, Eunhee 김은희, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, BAE, Hyun-Ju 배현주, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, BAE, Hyun-Ju 배현주, KIM, Jin-Woo 김진우, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, BAE, Hyun-Ju 배현주, KIM, Jin-Woo 김진우, IN, Tae-Kyu 인태규, KIM, Eunhee 김은희, YOO, Sung-Eun 유성은, KANG, Nam Sook 강남숙, KOO, Tae-Sung 구태성, PARK, Min-Young 박민영, KIM, Young-Hoon 김영훈, BAE, Hyun-Ju 배현주, KIM, Jin-Woo 김진우, IN, Tae-Kyu 인태규, JOO, Choun-Ki 주천기] 99, Daehak-ro 305-764 대전시 유성구 대학로 99, DaejeonYuseong-guDaejeon 305-764 The present invention relates to a novel methanone derivative, a preparation method for same, and a pharmaceutical composition, for preventing or treating retinal diseases, containing same as an active ingredient. A novel methanone derivative, an optical isomer of same, or pharmaceutically acceptable salts of same, according to the present invention, has excellent inhibitory efficiency of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). Therefore, a composition containing same as an active ingredient can be utilized as a pharmaceutical composition for preventing or treating retinal diseases such as retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardts disease, Usher syndrome, choroideremia, rod-cone or cone-rod dystrophy, ciliopathy, mitochondrial disorders, progressive retinal atrophy, degenerative retinal diseases, age-related macular degeneration (AMD), wet AMD, dry AMD, geographical atrophy, inherited or acquired macular degeneration, retinal photoreceptor diseases, retinal pigment epithelial diseases, diabetic retinopathy, cystic macular edema, uveitis, retinal detachment, traumatic retinal injury, iatrogenic retinal injury, macular holes, macular capillarectasia, ganglion cell diseases, optic nerve diseases, glaucoma, optic neuropathy, ischemic retinal diseases, retinopathy of prematurity, occlusion of retinal vessels, inherited macroaneurysm, retinal vascular diseases, ophthalmic vascular diseases, glaucomatous retinal neurodegeneration, ischemic optic neuropathy and the like.

[CHANG, Jin Sook 장진숙, CHANG, Jin Sook 장진숙, KIM, Ju Eun 김주은, CHANG, Jin Sook 장진숙, KIM, Ju Eun 김주은, KIM, So Young 김소영, CHANG, Jin Sook 장진숙, KIM, Ju Eun 김주은, KIM, So Young 김소영, NA, Kwang Ho 나광호, CHANG, Jin Sook 장진숙, KIM, Ju Eun 김주은, KIM, So Young 김소영, NA, Kwang Ho 나광호, SHIN, Yong Uk 신용욱, CHANG, Jin Sook 장진숙, KIM, Ju Eun 김주은, KIM, So Young 김소영, NA, Kwang Ho 나광호, SHIN, Yong Uk 신용욱, LEE, Jae Min 이재민, CHANG, Jin Sook 장진숙, KIM, Ju Eun 김주은, KIM, So Young 김소영, NA, Kwang Ho 나광호, SHIN, Yong Uk 신용욱, LEE, Jae Min 이재민, LEE, Jae Hee 이재희, CHANG, Jin Sook 장진숙, KIM, Ju Eun 김주은, KIM, So Young 김소영, NA, Kwang Ho 나광호, SHIN, Yong Uk 신용욱, LEE, Jae Min 이재민, LEE, Jae Hee 이재희, HEO, In Kyung 허인경] (Ssangnim-dong) 330, Dongho-ro 100-400 서울시 중구 동호로 330 (쌍림동), SeoulJung-gu,Seoul 100-400 The present invention relates to a recombinant microorganism producing quinolinic acid - in particular, a microorganism producing quinolinic acid and having a protein of SEQ ID NO: 1, the activity of which is reduced or removed, and to a method for producing quinolinic acid using the same.

[YOON, Joon Sun 윤준선, YOON, Joon Sun 윤준선, LEE, Hwa Jin 이화진, YOON, Joon Sun 윤준선, LEE, Hwa Jin 이화진, YI, Kye Sook 이계숙, YOON, Joon Sun 윤준선, LEE, Hwa Jin 이화진, YI, Kye Sook 이계숙, KIM, Cheol Min 김철민, YOON, Joon Sun 윤준선, LEE, Hwa Jin 이화진, YI, Kye Sook 이계숙, KIM, Cheol Min 김철민, LIM, Byung Pil 임병필, YOON, Joon Sun 윤준선, LEE, Hwa Jin 이화진, YI, Kye Sook 이계숙, KIM, Cheol Min 김철민, LIM, Byung Pil 임병필, CHANG, Shin Jae 장신재, YOON, Joon Sun 윤준선, LEE, Hwa Jin 이화진, YI, Kye Sook 이계숙, KIM, Cheol Min 김철민, LIM, Byung Pil 임병필, CHANG, Shin Jae 장신재, HONG, Seung Suh 홍승서] 19, Academy-ro 51 22014 인천시 연수구 아카데미로 51번길 19, IncheonYeonsu-guIncheon 22014 The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.

[LEE, Jae Min 이재민, LEE, Jae Min 이재민, KIM, Ju Eun 김주은, LEE, Jae Min 이재민, KIM, Ju Eun 김주은, LEE, Jae Hee 이재희, LEE, Jae Min 이재민, KIM, Ju Eun 김주은, LEE, Jae Hee 이재희, CHANG, Jin Sook 장진숙, LEE, Jae Min 이재민, KIM, Ju Eun 김주은, LEE, Jae Hee 이재희, CHANG, Jin Sook 장진숙, KIM, So Young 김소영, LEE, Jae Min 이재민, KIM, Ju Eun 김주은, LEE, Jae Hee 이재희, CHANG, Jin Sook 장진숙, KIM, So Young 김소영, SHIN, Yong Uk 신용욱] 330, Dongho-ro, 04560 서울시 중구 동호로 330, SeoulJung-gu,Seoul 04560 The present invention provides: an Escherichia sp. Microorganism having a quinolinic acid production ability, and transformed so as to have Klebsiella pneumonia-derived quinolinate synthase activity; and a method for producing quinolinic acid by using the microorganism.

[RA, Jeong Chan 라정찬, RA, Jeong Chan 라정찬, KANG, Sung Keun 강성근, RA, Jeong Chan 라정찬, KANG, Sung Keun 강성근, KIM, Sung-Min 김성민, RA, Jeong Chan 라정찬, KANG, Sung Keun 강성근, KIM, Sung-Min 김성민, LEE, Mi Sook 이미숙, RA, Jeong Chan 라정찬, KANG, Sung Keun 강성근, KIM, Sung-Min 김성민, LEE, Mi Sook 이미숙, LEE, Jin Hwa 이진화, RA, Jeong Chan 라정찬, KANG, Sung Keun 강성근, KIM, Sung-Min 김성민, LEE, Mi Sook 이미숙, LEE, Jin Hwa 이진화, KWON, Soon Ae 권순애] 10, Gukhoe-daero 76-gil 07238 서울시 영등포구 국회대로 76길 10, SeoulYeongdeungpo-guSeoul 07238 The present invention relates to a medium composition for culturing stem cells and, more specifically, to a medium composition, containing a base medium mixed with various semi-complete media (DMEM, a-MEM, IMDM, F12, and DMEM/F12), L-ascrobic acid 2-phosphoric acid, bovine fatal serum, basic fibroblast growth factor (b-FGF), insulin, N-acetyl-L-cysteine, chloride calcium, and hydrocortisone, for culturing mesenchymal stem cells. According to the present invention, the differentiation ability and proliferation ability of the mesenchymal stem cells can be improved, and the mesenchymal stem cells can be cultured at a lower price compared with an existing culturing method, and thus a cell therapeutic agent using mesenchymal stem cells can be more economically produced.

[MOON, Ji Sook 문지숙, MOON, Ji Sook 문지숙, KIM, Chul 김철, MOON, Ji Sook 문지숙, KIM, Chul 김철, PARK, Ji Min 박지민, MOON, Ji Sook 문지숙, KIM, Chul 김철, PARK, Ji Min 박지민, BAE, Sang Hun 배상훈] 120, Haeryong-ro 11160 경기도 포천시 해룡로 120, Gyeonggi-doPocheon-si,Gyeonggi-do 11160 The present invention relates to placenta-derived cells excreting C3 or C1R complement proteins, a pharmaceutical composition containing same, and a method for treating diseases using the placenta-derived cells. The placenta-derived cells, according to the present invention, can be effectively applied to Alzheimer's disease, Parkinson's disease, HIV, neurodegenerative diseases such as dementia and epilepsy, or angiogenesis-related diseases such as cancer and retinopathy, thereby having high industrial utility.

[KIM, Geun Tae, KIM, Geun Tae, KIM, Kang Min, KIM, Geun Tae, KIM, Kang Min, PARK, Ki Sook, KIM, Geun Tae, KIM, Kang Min, PARK, Ki Sook, PARK, So La] LG Gwanghwamun Bldg.58, Saemunan-roJongno-guSeoul 03184 The present invention relates to the provision of a pharmaceutical preparation having improved stability in solution by improving the solubility of indole compound. A pharmaceutical preparation comprising an indole compound or a pharmaceutically acceptable derivative thereof, a cyclodextrin derivative and an antioxidant renders indole compounds―which have low aqueous solubility and are unstable in water―capable of parenteral administration via the improvement of the solubility and stability in solution of indole compounds by forming as an inclusion complex of cyclodextrin derivative. The pharmaceutical preparation may be preferably used for inhibiting cellular necrosis and preventing ischemia/reperfusion injury. Specifically, fatal reperfusion cardiac injury by percutaneous coronary intervention (PCI) operation can be basically prevented or treated by the pre-treatment.

[KIM, Ho Sung 김호성, KIM, Ho Sung 김호성, KIM, Min Young 김민영, KIM, Ho Sung 김호성, KIM, Min Young 김민영, KANG, Byeong Su 강병수, KIM, Ho Sung 김호성, KIM, Min Young 김민영, KANG, Byeong Su 강병수, YANG, Sun Woo 양선우, KIM, Ho Sung 김호성, KIM, Min Young 김민영, KANG, Byeong Su 강병수, YANG, Sun Woo 양선우, NOH, Hee Sook 노희숙] 89, Yangdaegiro-gil, Ipjang-myeon, Seobuk-gu 31056 충청남도 천안시 서북구 입장면 양대기로길 89, Chungcheongnam-doCheonan-siChungcheongnam-do 31056 The present invention relates to a preparation method for a bipolar plate for a redox flow battery. To this end, the present invention comprises the steps of: (a) preparing a mixture by mixing epoxy, a curing agent, and a conductive filler; and (b) preparing a bipolar plate comprising a conductive filler composite that has been prepared by compression molding the mixture.

[KIM JONG-GI, KIM MIN-SUNG, KIM DONG-JUN, JEONG JI-YOUNG, CHUNG MIN-KYEOL, JANG HYUN-SOOK, PARK MIN-JEE, KIM MIN-GI, MIN GYEONG-SEO, LEE BUM-JIN] KR Provided are a curable composition, a cured layer manufactured using the curable composition, a color filter including the cured layer, and a display device including the color filter, the curable composition including (A) quantum dots; and (B) a polymerizable compound including a compound represented by Chemical Formula 1. In Chemical Formula 1, each substituent is as defined in the specification.